BioVersys AG (XSWX:BIOV) Tax Provision: CHF-0.02 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:BIOV BioVersys AG XSWX:BIOV
4 GF Score
Price CHF27.70
View Full Analysis

What is BioVersys AG Tax Provision?

BioVersys AG XSWX:BIOV +0.73% 4 Tax Provision is CHF-0.02 Mil as of Dec. 2025. GuruFocus rates XSWX:BIOV with a GF Score™ of 4/100.

BioVersys AG's tax provision for the six months ended in Dec. 2025 was CHF-0.02 Mil. Its tax provision for the trailing twelve months (TTM) ended in Dec. 2025 was CHF-0.02 Mil.

BioVersys AG Tax Provision Historical Data

* Premium members only.

The historical data trend for BioVersys AG's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioVersys AG Tax Provision Chart

BioVersys AG Annual Data
Trend Dec24 Dec25
Tax Provision
0.00 -0.02

BioVersys AG Semi-Annual Data
Jun24 Dec24 Jun25 Dec25
Tax Provision 0.00 0.00 0.00 -0.02
XSWX:BIOV
4GF Score
BioVersys AG XSWX:BIOV
Tax Provision is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioVersys AG Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF-0.02 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Tax Provision →
What does a Tax Provision of CHF-0.02 Mil mean?
BioVersys AG (XSWX:BIOV) has a Tax Provision of CHF-0.02 Mil as of Dec. 2025. Provision for taxes is the amount of tax the company owes based on pre-tax income. View historical data on BioVersys AG and its competitors.
Is BioVersys AG's Tax Provision too high?
BioVersys AG's current Tax Provision is CHF-0.02 Mil. Overall, BioVersys AG has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does BioVersys AG's Tax Provision compare to VRTX and REGN?
BioVersys AG's Tax Provision of CHF-0.02 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tax Provision for a Biotechnology company?
A good Tax Provision depends on the Biotechnology industry context. However, Tax Provision should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tax Provision mean?
A high Tax Provision can signal that a stock is expensive relative to its fundamentals. Provision for taxes is the amount of tax the company owes based on pre-tax income. View historical data on BioVersys AG and its competitors. BioVersys AG's current Tax Provision is CHF-0.02 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioVersys AG stock overvalued right now?
BioVersys AG (XSWX:BIOV) has a current Tax Provision of CHF-0.02 Mil. The current Tax Provision is CHF-0.02 Mil. BioVersys AG's overall GF Score™ is 4/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tax Provision calculated?
Tax Provision is calculated from a company's financial statements. For BioVersys AG (XSWX:BIOV), the current Tax Provision is CHF-0.02 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BioVersys AG Business Description

Other Exchanges BIOVz:UKW33:Germany
Address c/o Technologiepark, Hochbergerstrasse 60c, Basel, CHE, CH-4057
BioVersys AG is a multi-asset, clinical-stage biopharmaceutical company. The Group focuses on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria. The pipeline products of the company include BV100 - novel MoA, Alpibectir - novel potentiator MoA, BV200 - novel anti-virulence MoA, BV500 - novel series, and others. It has one operating segment focusing on the research and development and prospective commercialization of antibiotics. Geographically, the company operates in Switzerland and France.
4GF Score

Get the complete analysis for XSWX:BIOV

Tax Provision is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF27.70
Price